Lumos Diagnostics Holdings's quarterly market cap
declined
from Dec. 2024 ($22.46 Mil) to Jun. 2025 ($12.05 Mil) but then
increased
from Jun. 2025 ($12.05 Mil) to Dec. 2025 ($160.83 Mil).
Lumos Diagnostics Holdings's annual market cap
increased
from Jun. 2023 ($2.75 Mil) to Jun. 2024 ($13.52 Mil) but then
declined
from Jun. 2024 ($13.52 Mil) to Jun. 2025 ($12.05 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Lumos Diagnostics Holdings's Enterprise Value for Today is $67.27 Mil.
Lumos Diagnostics Holdings (OTCPK:LDXHF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Lumos Diagnostics Holdings Market Cap Related Terms
Lumos Diagnostics Holdings Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Lumos Diagnostics Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumos Diagnostics Holdings Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lumos Diagnostics Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where Lumos Diagnostics Holdings's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumos Diagnostics Holdings (LDXHF) has a Market Cap of $63.80 Mil as of Jul. 12, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Lumos Diagnostics Holdings and its competitors. According to the industry distribution chart, Lumos Diagnostics Holdings ranks #500 out of 866 companies in the Medical Devices & Instruments industry, placing it in the top 57.7%.
Is Lumos Diagnostics Holdings' Market Cap too high?
Lumos Diagnostics Holdings' current Market Cap is $63.80 Mil. The Medical Devices & Instruments industry median Market Cap is 119.91. Lumos Diagnostics Holdings' value of $63.80 Mil is 46.8% below this industry median. Based on the distribution chart, Lumos Diagnostics Holdings ranks #500 out of 866 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Lumos Diagnostics Holdings has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lumos Diagnostics Holdings' Market Cap compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Lumos Diagnostics Holdings ranks #500 out of 866 companies for Market Cap. This places Lumos Diagnostics Holdings in the lower half of its industry. The industry median Market Cap is 119.91. Lumos Diagnostics Holdings' value of $63.80 Mil is 46.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 119.91, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lumos Diagnostics Holdings's current Market Cap of $63.80 Mil is 46.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Lumos Diagnostics Holdings and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 119.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumos Diagnostics Holdings's current Market Cap is $63.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumos Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings (LDXHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.11 — trading 441% above its estimated fair value. The current Market Cap is $63.80 Mil and 46.8% below the Medical Devices & Instruments industry median of 119.91. Lumos Diagnostics Holdings' overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Lumos Diagnostics Holdings (LDXHF), the current Market Cap is $63.80 Mil as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumos Diagnostics Holdings (LDXHF) Overvalued in 2026?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings stock appears to be overvalued.
The current stock price of $0.11 is trading 441% above its estimated GF Value™ of $0.02.
GuruFocus considers Lumos Diagnostics Holdings to be Significantly Overvalued.
Key valuation signals for LDXHF:
Market Cap: $63.80 Mil
GF Value™: $0.02 vs. price of $0.11 (441% above fair value)
Industry Position: 46.8% below the Medical Devices & Instruments median (#500 of 866)
No single metric tells the full story. See the LDXHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.
29GF Score
Get the complete analysis for LDXHF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LDXHF has been successfully added to your 
